Welcome to our dedicated page for Actinium Pharmaceuticals SEC filings (Ticker: ATNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Actinium Pharmaceuticals filings document governance and public-company reporting for a biopharmaceutical issuer whose common stock is registered on the NYSE American under ATNM. Recent Current Reports and proxy materials cover annual meeting matters, Class III director elections, advisory votes on executive compensation, principal financial officer changes, and registered common stock details.
The company's proxy disclosures connect shareholder voting matters with board structure, compensation oversight, and annual-report materials. Form 8-K filings record material events and amendments to prior event reports, including officer-transition disclosures and the final reporting of annual meeting voting outcomes.
Actinium Pharmaceuticals, Inc. (ATNM) reported the initial equity holdings of Chief Scientific Officer Kamal Adeela. The filing lists 213,648 shares of Common Stock in the form of restricted stock units and stock options over 120,000 shares of Common Stock.
Of the restricted stock units, 80,000 vest in three equal installments on September 2, 2027, September 2, 2028 and September 2, 2029, and 133,648 vest on September 2, 2029. The stock options have an exercise price of $1.00 per share, vest in fifty equal monthly tranches beginning on October 2, 2026, and expire on September 2, 2036.
Actinium Pharmaceuticals, Inc. (ATNM) reported the initial beneficial ownership of its Chief Medical Officer, Steffen Wilhem Heeger, on a Form 3. Heeger holds 153,868 shares of Common Stock in the form of restricted stock units that vest fully on September 2, 2029, and a stock option for 250,000 shares of Common Stock with an exercise price of $1.15 per share, expiring May 28, 2036. According to the disclosure, 28% of these options vest on May 28, 2027, with the remainder vesting in 36 equal monthly tranches thereafter.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Shetty Ajit reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Ajit Shetty received equity awards on September 2, 2026. He was granted 61,600 shares of Common Stock as restricted stock units, which vest in three equal annual installments, and 92,400 stock options exercisable at $1.00 per share that vest in fifty equal monthly tranches. Following these awards, he holds 62,357 shares of Common Stock directly and 92,400 stock options. No Rule 10b5-1 trading plan is reported.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director C. David Nicholson received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. Following these awards, he holds 63,300 shares of Common Stock directly.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Almenoff June Sherie reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director June Sherie Almenoff received equity awards on September 2, 2026 under a Rule 10b5-1 trading plan. She was granted 18,000 shares of common stock in the form of restricted stock units and 27,000 stock options to buy common shares at $1.00 per share.
The restricted stock units vest in three equal annual installments over three years, and the options vest in fifty equal monthly installments beginning on the grant date and expire on September 2, 2036. Following these awards, she directly holds 18,000 common shares and 27,000 options related to these grants.
Actinium Pharmaceuticals, Inc. (ATNM) reported that Chief Executive Officer and director Sandesh Seth received significant equity awards on September 2, 2026. He was granted stock options to acquire 1,130,400 shares of common stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. He also received 753,600 restricted stock units that vest in three equal annual installments and 1,027,274 restricted stock units that vest fully on the third anniversary of the grant date. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Richard I. Steinhart received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years, resulting in 63,116 Common shares held directly after the grant. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) director Jeffrey W. Chell received equity awards on September 2, 2026, consisting of 61,600 shares of Common Stock in the form of restricted stock units and 92,400 stock options with a $1.00 exercise price expiring September 2, 2036. The RSUs vest in three equal annual installments, while the options vest in fifty equal monthly tranches beginning on the grant date. No Rule 10b5-1 trading plan is reported.
Actinium Pharmaceuticals, Inc. reports that NYSE Regulation has accepted its compliance plan, granting a plan period through November 27, 2027 to regain compliance with NYSE American continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii). During this period, the common stock will continue to trade on NYSE American under the symbol ATNM, subject to ongoing compliance with other listing requirements and periodic NYSE review. Failure to regain compliance or demonstrate satisfactory progress may lead to delisting proceedings.
Actinium also highlights advances in its Actimab-A radiotherapy program, including multiple newly issued and allowed patents in the United States and internationally, with terms extending into 2037–2043, covering uses in AML, MDS and solid tumors via myeloid-derived suppressor cell targeting. The company has amended its IND to add an additional manufacturer to support studies under its CRADA with the National Cancer Institute and company-sponsored trials, aiming to expand manufacturing capacity as clinical milestones approach from late 2026 into 2027. Actinium states it has about 250 patents and patent applications across its portfolio.
Actinium Pharmaceuticals reported a sharp swing to profitability for the quarter ended June 30, 2026 after recognizing previously deferred license revenue. Total revenue was $35.0 million, all from Immedica Pharma’s upfront payment under the Iomab‑B license, driving net income of $27.9 million, or $0.89 per diluted share, versus a $6.9 million loss a year earlier. For the first six months of 2026, revenue was $35.0 million and net income was $22.4 million, compared with a $22.8 million loss in the prior‑year period.
Despite the accounting profit, operations used $11,049 thousand of cash in the first half, and cash, cash equivalents and restricted cash declined to $36,812 thousand from $48,333 thousand at year‑end 2025. Total liabilities fell to $9,855 thousand as the $35.0 million long‑term license revenue deferred balance was eliminated, increasing stockholders’ equity to $30,302 thousand. Research and development expenses were $9,578 thousand and general and administrative expenses $3,760 thousand for the six‑month period. The company highlights a broad radiotherapy pipeline, including ATNM‑400 for solid tumors, Actimab‑A for AML, MDS and immuno‑oncology combinations, and CD45‑targeted conditioning agents Iomab‑B and Iomab‑ACT, with multiple data readouts expected from late 2026 into 2027.